Amgen Inc. (AMGN) stock forecast and price target
Price $465.67 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($465.67)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $23.53 | +7.8% | $39.5B |
| Next fiscal year ends December 31, 2027 | $25.06 | +6.5% | $41.3B |
| Next quarter ends December 31, 2026 | $5.64 | +6.7% | $10.5B |
| Quarter after ends March 31, 2027 | $5.72 | +11.1% | $9.5B |
Consensus of the analysts covering Amgen, updated daily. In the last 30 days 25 estimates were raised and 2 lowered.
Our model vs. Wall Street
Analysts see 7.3% downside over 12 months. Our discounted cash flow model with moderate assumptions puts Amgen’s intrinsic value about 26% below today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Amgen stock price target?
The average 12-month target from 29 analysts is $431.81, 7.3% below the current price of $465.67 Targets range from $230.00 to $536.00.
Is Amgen a buy according to analysts?
The consensus rating is “Hold” (4 strong buy, 7 buy, 18 hold, 3 sell, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Amgen expected to earn?
Analysts expect EPS of $23.53 for the fiscal year ending December 31, 2026 and $25.06 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.